Parabilis Medicines Achieves First-Ever Clinical Success Targeting "Undruggable" β-Catenin:TCF Interaction with FOG-001
核心洞察
Parabilis Medicines (搜索)' FOG-001 becomes the first therapy to successfully drug the β-catenin (搜索):TCF (搜索) interaction, a key cancer driver considered "undruggable" for over 30 years and implicated in millions of cancer cases annually.
Phase 1/2 clinical trial data shows FOG-001 achieved 100% tumor reduction in desmoid patients with an 80% objective response rate, demonstrating meaningful anti-tumor activity across multiple Wnt/β-catenin (搜索)-driven solid tumors.
The breakthrough validates Parabilis' Helicon™ peptide platform technology, which uses stabilized α-helical peptides to penetrate cells and target previously inaccessible protein-protein interactions.
Parabilis Medicines (搜索) has achieved a significant breakthrough in cancer therapeutics by successfully targeting the β-catenin (搜索):TCF (搜索) interaction, a critical cancer-driving mechanism that has remained "undruggable" for over three decades. The company's investigational therapy FOG-001 demonstrated unprecedented clinical activity in patients with Wnt/β-catenin-driven tumors, marking the first time this fundamental cancer pathway has been successfully targeted in humans.
Clinical Trial Results Demonstrate Unprecedented Activity
In the ongoing Phase 1/2 trial of FOG-001, preliminary data as of mid-August 2025 showed remarkable efficacy across multiple tumor types. Among 12 patients with desmoid tumors (搜索) dosed across three dose levels, tumor reductions were observed at all dose levels with a 100% disease-control rate. Of the five patients with more than one post-baseline scan, an objective response rate of 80% was achieved per RECIST 1.1 criteria.
The therapy demonstrated activity in both gamma secretase-naive and previously treated patients, with clinically meaningful anti-tumor activity alongside acceptable safety and tolerability profiles. No Grade 4/5 treatment-related adverse events or discontinuations were reported in the early data.
Broad Activity Across Wnt-Driven Cancers
Beyond desmoid tumors (搜索), FOG-001 showed single-agent activity resulting in tumor shrinkage of at least 30% across five low-complexity tumor types, including adamantinomatous craniopharyngioma (搜索), ameloblastoma (搜索), salivary gland cancer (搜索), and solid pseudopapillary neoplasm (搜索). In non-colorectal cancer (搜索) patients with Wnt pathway activating mutations, the therapy achieved a 43% objective response rate and 73% disease control rate.
"For decades, scientists had said that the Wnt/β-catenin (搜索):TCF (搜索) interaction couldn't be drugged, but our data prove otherwise," said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines (搜索). "FOG-001 shows what bold science can achieve — taking on one of cancer's most important drivers and opening the door to an entirely new class of therapies."
Mechanism of Action and Platform Technology
FOG-001 achieves its therapeutic effect by blocking the interaction between β-catenin (搜索) and the T-cell factor (TCF (搜索)) family of transcription factors, the key driver of tumorigenesis in Wnt pathway-activated cancer cells. This represents a direct approach to addressing the underlying mechanism of disease through β-catenin inhibition, unlike other available therapies.
The therapy is built on Parabilis' proprietary Helicon™ platform, which has overcome limitations of traditional small molecule therapeutics by designing stabilized α-helical peptides that can penetrate cells and bind tightly to proteins with relatively flat binding surfaces. This technology enables targeting of protein-protein interactions that were previously considered inaccessible to conventional drug approaches.
Potential in Complex Cancers and Combination Therapy
In microsatellite-stable colorectal cancer (搜索) (MSS CRC), FOG-001 achieved a 50% disease control rate within the efficacious monotherapy dose range. Molecular data confirmed on-target pathway inhibition and reprogramming of the tumor microenvironment toward a more immune-active state.
Complementary preclinical studies demonstrated that FOG-001 enhances the effects of standard and emerging therapies for MSS CRC, showing additive or synergistic activity with 5-fluorouracil and anti-VEGF regimens, synergy with anti-PD-1 therapy, and combination benefit with pan-RAS and KRAS G12D inhibitors.
Expanding Pipeline in Prostate Cancer
Parabilis also presented preclinical data advancing its prostate cancer (搜索) franchise, targeting two historically undruggable oncogenic drivers. ERG (搜索)-degrading Helicon peptides potently and durably reduced ERG protein levels, which are overexpressed in 40-50% of prostate cancers, showing tumor growth inhibition and efficacy comparable to or exceeding standard of care in challenging prostate cancer models.
The company's allosteric ARON (搜索) Helicon degraders selectively target the active, agonist-bound androgen receptor (搜索) through a conserved site distinct from the androgen ligand pocket. These degraders block proliferation in AR-amplified prostate cancer (搜索) cells, offering a strategy to overcome resistance driven by AR mutations or amplification.
Clinical Development Path Forward
The Wnt/β-catenin pathway (搜索), first identified over 30 years ago as a fundamental driver of cancer, is implicated in millions of cases annually across both common cancers including gastrointestinal cancers like colorectal, hepatocellular, and gastric cancers, as well as many rare cancers such as desmoid tumors (搜索) and adamantinomatous craniopharyngioma (搜索).
The Phase 1/2 study continues to enroll patients across a wide range of Wnt-driven rare and common cancers, with additional data readouts expected over the coming months. The findings support continued development of FOG-001 in Wnt pathway-activated low-complexity tumors and as a backbone for rational combination regimens in more complex cancers.